News
OCS
27.48
0.00%
0.00
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Barchart · 1d ago
Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG) and Oculis Holding (OCS)
TipRanks · 3d ago
Weekly Report: what happened at OCS last week (0420-0424)?
Weekly Report · 5d ago
Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing
TipRanks · 6d ago
Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session
TipRanks · 04/21 20:28
Oculis Publishes Invitation to the Annual General Meeting
Barchart · 04/21 15:05
Oculis Buy Rating Reiterated on De-Risked Phase 3 DIAMOND Program and Blockbuster Potential of Topical DME Therapy OCS-01
TipRanks · 04/20 18:45
Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Pasithea Therapeutics Corp (KTTA)
TipRanks · 04/20 16:40
Oculis Holding Price Target Maintained With a $44.00/Share by HC Wainwright & Co.
Dow Jones · 04/20 16:40
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $44 Price Target
Benzinga · 04/20 16:30
Weekly Report: what happened at OCS last week (0413-0417)?
Weekly Report · 04/20 10:21
Oculis Completes Last Patient Visit In Phase 3 DIAMOND For OCS-01 Eye Drops In D. Macular Edema
NASDAQ · 04/20 09:53
Oculis Completes Final Patient Visits In Both Phase 3 DIAMOND Trials For OCS-01 Diabetic Macular Edema Eye Drop Treatment
Benzinga · 04/20 09:31
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
Barchart · 04/20 03:00
Oculis Holding: Needham Conference Visibility Reinforces Buy Rating and Upside Potential
TipRanks · 04/15 09:56
Weekly Report: what happened at OCS last week (0406-0410)?
Weekly Report · 04/13 10:25
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Barchart · 04/08 15:05
Oculis to Participate in Upcoming Investor Conferences
Barchart · 04/07 03:00
Weekly Report: what happened at OCS last week (0330-0403)?
Weekly Report · 04/06 10:25
Oculis Receives European Medicines Agency PRIME Designation For Privosegtor In Optic Neuritis, Accelerating PIONEER Registrational Program Across Three Global Trials
Benzinga · 03/31 08:10
More
Webull provides a variety of real-time OCS stock news. You can receive the latest news about Oculis Holding through multiple platforms. This information may help you make smarter investment decisions.
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.